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Abstract:
Purpose: The purpose of this study was to assess the validity of a modified Partner Violence
Screen (PVS) for measuring severe lifetime and past-year intimate partner violence (IPV)
victimization among female trauma patients.
Background: Intimate partner violence (IPV) is a major medical and public heath problem that
affects as many as 5.3 million U.S. women annually. However, recent studies report that as few
as 7% of women have ever been asked about IPV by a health care provider. Brief screening
tools have been developed to increase screening by health care providers.
Methods: A cross-sectional study was conducted at the University of New Mexico Hospital
Trauma Center. Face-to-face interviews were conducted with a racially/ethnically diverse
sample of 197 women who were admitted to the level 1 regional trauma service from April 2003
through June 2005. Statistical analyses were performed to assess the sensitivity and specificity of
the PVS for measuring severe lifetime and past-year IPV, using the severe items of the revised
Conflict Tactics Scale (CTS2) as the gold standard. Validity of the PVS for measuring severe
lifetime IPV was also assessed separately for Hispanics, Native Americans, and White nonHispanics.
Results: In the entire study sample, the PVS had a sensitivity of 80.6% (95% confidence
interval [CI]: 70.9-87.8%) and a specificity of 95.1% (95% CI: 88.5-98.2%) for detecting any
lifetime severe IPV, and a sensitivity of 70.3% (95% CI: 52.8-83.6%) and a specificity of 97.4%
(95% CI: 92.1-99.3%) for detecting any past-year severe IPV. The PVS had sensitivity of 77.885.7% and a specificity of 93.5-96% when examining Hispanic, Native American, and White
non-Hispanic women individually.
Conclusion: The PVS is a valid screening tool for measuring severe lifetime IPV in Hispanic,
Native American, and White, non-Hispanic female trauma patients. The PVS had lower
sensitivity for measuring severe IPV in the past year and thus may not be as valid for measuring
recently experienced IPV. More research needs to be conducted with larger samples to
determine appropriate screening tools to further prevent and help victims of IPV.
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Introduction
Intimate Partner Violence as a Medical Problem
Intimate Partner Violence (IPV) is a major health problem in the United States that results in
acute injuries, chronic health and mental health problems, and in some cases, death.1,2 IPV has
been defined as, “actual or threatened physical, sexual, psychological, or emotional abuse by a
current or former spouse (including common-law spouse), dating partner, boyfriend or
girlfriend.”1 According to the National Violence Against Women Survey (NVAWS), 5.3 million
intimate partner violence victimizations occur among U.S. women ages 18 and older each year.2
Nearly 25% of women surveyed reported being raped and/or physically assaulted by an intimate
partner at some point in their lives. More than 40% of the women who experienced partner rapes
and/or physical assault sustained a physical injury. These assaults result in nearly 2 million
injuries per year, 550,000 or more requiring medical attention, and in nearly 1300 deaths.2

Intimate partner violence not only accounts for physical and emotional injuries, chronic health
problems, and death, it also has a major economic impact on our society. The costs of IPV
exceed $5.8 billion each year.3 Nearly $4.1 billion is for direct medical and mental health care
services. IPV also accounts for 8 million days of lost paid work and 5.6 million days of lost
household productivity.3 Studies have also found that victims of IPV cost health plans 92% more
than general female patients.4 Frequent visits to the emergency department, hospital stays, and
mental health services comprise most of these increased costs.
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IPV Screening Instruments
Many organizations, including the Centers for Disease Control and Prevention5, College of
Obstetricians and Gynecologists6, and the American Medical Association7 recommend screening
women in clinical settings for IPV in order to identify and help victims. Despite these
recommendations, recent studies have shown that only 7% of women reported that they were
ever asked about IPV by a health care professional.8 Proposed reasons as to why screening rates
are low include healthcare providers fear of offending or angering the victim, lack of training,
lack of time, and the belief that IPV is not a problem in their current patient population.9 Siegel
et al demonstrated that a majority of women in their sample population which consisted of
women at one of two urban clinics actually favored routine inquiry by a health care provider
about physical or sexual abuse.10 Only 7.9-9.5% of women stated they would feel angry or
offended if questioned about IPV by a health care professional.11, 12 In a study conducted by
Weinsheimer et al, 90.9% of women stated that talking to a trauma center health care provider
about IPV issues would help them figure out what they needed to do to be safe from the person
who harmed them. 12

Various screening methods have been introduced to identify victims of IPV. The Conflict
Tactics Scale (CTS) was introduced in 1979 by Straus as a way to measure violence within
familial situations.13 In 1996, the Conflict Tactics Scale was revised (CTS2) to include questions
that measure sexual coercion and physical injury, items to enhance content validity and
reliability, better differentiation between minor and severe levels of each scale, and revised
wording to increase clarity and specificity of the questions. However, the complete CTS2 is
comprised of 78 questions encompassing 5 scales: negotiation, psychological aggression,
physical violence, sexual coercion and injury, 14 and thus can take a lot of time to administer.
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In situations where there is not much time to administer a screen for various reasons, brief
screening instruments have been developed to quickly identify victims of IPV. The Index of
Spouse Abuse (ISA)15, Hurt, Insulted, Threatened, or Screamed at (HITS)16, the Abuse
Assessment Screen (AAS)17, and the Partner Violence Screen (PVS)18 are all screening tools that
have been developed to screen for IPV. The PVS is frequently used in emergency departments
and will be the focus of this study.

In 1997, Feldhaus et al introduced the PVS.18 The PVS consists of three questions, including a
single question that addresses physical violence, “Have you been hit, kicked, punched or
otherwise hurt by someone within the past year?”. The last two questions address a woman’s
perception of her safety, “Do you feel safe in your current relationship?” and “Is there a partner
from a previous relationship who is making you feel unsafe now?”.18 Feldhaus’ initial study
found that the PVS had a sensitivity of 71.4% and a specificity of 84.4% when compared to the
Conflict Tactics Scales.18 The 322 women surveyed were patients in two urban emergency
departments in Colorado. This screening tool has since been widely used in emergency
departments as a quick and easy way to screen for IPV.

Only a few studies have tested the validity of the PVS in settings other than emergency
departments. In 2001, Koziol-McLain et al19 examined the validity of the PVS in predicting
future IPV among women who had participated in a population-based, statewide telephone
survey. The PVS in this study was measured against items from both the CTS and CTS2. This
study showed that the PVS had a sensitivity of 80% and a specificity of 93% when compared to
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the CTS for predicting future severe physical IPV.18 In 2004, Houry et al20 measured the ability
of the PVS to predict future assaults and violence against women. The study participants were
female emergency department patients who were screened for domestic violence. The study
found that women who screened positive for IPV on the PVS were 11 times more likely to
experience violence from a current or past partner over the next four months.21

A study measuring the validity of the PVS has not been conducted in the southwestern United
States. Southwestern states have very diverse populations. For example, when compared to the
rest of the United States, New Mexico’s population has a much higher percent of persons of
Hispanic or Latino origin (42.1% vs. 12.5% for U.S.) and of American Indian or Alaska Native
descent (9.5% vs. 0.9% for U.S.).21 Much of the state is made up of rural communities, most
lacking adequate health care. A recent study conducted by Hazen et al investigated IPV among
Latina women in California. They reported that 33.9% of Latina women studied experienced
physical violence, 20.9% experienced sexual coercion and 82.5% experienced psychological
aggression by an intimate partner at some time in the lifetime. 22 Malcoe et al found that 58.9%
of Native American women surveyed in Oklahoma reported lifetime physical and/or sexual IPV,
39.1% experienced severe physical IPV, 12.2% reported partner-forced sexual activity, and
40.1% reported lifetime partner perpetrated injuries.23 The rates reported by both Hispanics and
Native American women in these studies are much higher than those reported in the National
Violence Against Women Survey.2

Further, New Mexico has a very high IPV rate. The 1998 Pregnancy Risk Assessment
Monitoring System (PRAMS) surveillance report provided by the Division of Reproductive
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Health at the Centers for Disease Control found that 8.2% of women in New Mexico reported
being physically abused by their husbands or partner during the 12 months before their
pregnancy.24 This rate was the highest reported out of all 15 states that were included in the
survey; rates in the other 14 states ranged from 3.6% - 7.4%. According the New Mexico
Coalition Against Domestic Violence, 25,644 cases of IPV were reported in 2003. A total of
75% of these victims were female, and 4450 cases resulted in injuries.25

In order to establish the PVS as a valid screening method, more studies need to be conducted in
diverse patient populations across the country, particularly in areas with high rates of IPV.

Aims and Hypothesis:
Because of the high rate of IPV and severe trauma seen in New Mexico, the setting of our study
was the University of New Mexico UNMH Trauma Service. The purpose of this study was to
assess the validity of a modified PVS for measuring severe IPV victimization among female
trauma patients, using severe items of the CTS22 as the gold standard. In particular, we assessed
the validity of the modified PVS for measuring a) lifetime severe IPV and b) past-year severe
IPV. The corresponding hypothesis of this aim was that the sensitivity and specificity of the
modified PVS would be greater than 80% for measuring both severe lifetime IPV and severe IPV
occurring in the past 12 months.

A secondary aim of the study was to assess whether the modified PVS is equally valid in
measuring severe lifetime IPV in Hispanic, Native American, and non-Hispanic White
populations. The corresponding hypothesis for this aim was that the sensitivity and specificity of
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the modified PVS would be greater than 80% in measuring severe lifetime IPV among Hispanic,
Native American, and non-Hispanic White female trauma patients. Only lifetime severe IPV
was examined for this aim because of limited sample size within racial/ethnic groups.

Methods:
All English-speaking women ages 18-80 years who were admitted to the University of New
Mexico (UNMH) Trauma Service were considered for inclusion in the study. UNMH is the only
level I trauma center in the state of New Mexico and serves as the trauma center for southern
Colorado, eastern Arizona, and the Navajo Nation. Women were systematically identified from
the daily inpatient trauma rosters. The patients were eligible if they spoke English and were able
to read the introductory letter accompanying the survey. Women with head trauma and those
suffering from psychiatric disorders were ineligible to participate. Of female trauma patients
admitted between April 2003 and June 2005, 197 patients were interviewed as part of the study.

The interviews were conducted face-to-face, were administered by a female social worker,
female medical student or a male (n=5) or female physician. The interviews lasted
approximately 30 minutes and were completely anonymous. All interviews were administered
without visitors, family members, or partners in the room. In order to obtain consent without
identifying the participants, the women are asked read the introductory letter and to place the
introductory letter in an envelope to consent to participate. Participants were informed that they
could stop their participation at any point during the interview if any of the questions made them
feel uncomfortable.
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The survey instrument included a modified PVS and the severe items of the CTS2. The PVS
questions were asked before the CTS2 items. The original PVS is comprised of three
questions,10 which were modified for this study to measure IPV in the past year as well as in the
woman’s lifetime. The severe items of the CTS2 consisted of 14 questions that assessed severe
physical assault, sexual coercion, and injury. A question about receiving a bloody lip or black
eye was added to the original CTS2 items.19 The questions for the PVS and CTS22 used in this
study are provided in Table 1.

Demographic and socioeconomic information were collected for all women participating in the
study. To determine race/ethnicity, women were asked which racial or ethnic category best
described them. They were given the choices of: 1) American Indian/Alaskan Native, 2) Whitenon Hispanic, 3) Asian/Pacific Islander, 4) Black or African American, 5) Hispanic/Latino
(including Cuban, Puerto Rican, Mexican, New Mexican, and Spanish), or 6) Something else.

Data were collected by trained interviewers and entered into SPSS (version 10). Data entry
validation was performed by re-entering a random sample of 10% of previously entered surveys.
The responses from these surveys were compared with the original responses using SAS
statistical software. Responses that differed between the two data entries were looked up and
corrections were made to the original database. Of the 17 surveys that were randomly selected, 7
of those differed from the original dataset. When systematic key entry errors were identified,
corrections were made to the dataset.
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Statistical analyses were performed to assess the sensitivity and specificity of the modified PVS,
using the 14 severe CTS2 items as the gold standard (Table 1). Statistical analysis was
performed for the first aim as follows: Items in the CTS2 were counted separately from the PVS
and severe lifetime IPV and severe past-year IPV were assessed separately for each scale. For
items in the CTS2, never responses were counted as a 0 and constituted a negative response. If
an answer was > 0, it was considered a positive IPV response. For example, if a woman
answered > 0 to any CTS2 item (1-14) for the past 12 months, she was considered positive for
past-year severe IPV and for lifetime severe IPV (because if it happened in the past year, then it
happened in her lifetime). If she answered 0 to all 14 CTS2 items for the past year then she was
considered negative for past-year severe IPV. Likewise, if she answered 0 to all 14 CTS2 items
in her lifetime, then she was counted as negative for severe lifetime IPV. For items in the PVS, a
“no” was also a 0 or negative response. A “yes but not in the last year” response was considered
a positive response for lifetime severe IPV and a “yes in the past year” response was a positive
for past-year IPV.

Each calculation was entered separately into a table to calculate the sensitivity and specificity of
the modified PVS for measuring severe IPV. Separate tables were constructed for lifetime
severe IPV and for past-year severe IPV. For the second aim, the statistical analysis was
performed by calculating the sensitivity and specificity for lifetime IPV separately among
women who were Native American, Hispanic, and non-Hispanic Whites. Positive and negative
responses were entered into the following table to calculate sensitivity and specificity.
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+
PVS

CTS2
-

+

-

TP (a)

FP (b)

FN (c)

TN (d)

*TP= True positive, FP= False positive, FN= False negative, TN+ True Negative
Sensitivity = a/ (a+c)
Specificity = d/ (b+d)

A Priori Power Calculation:
As part of the design for this study’s hypothesis, we used information from the first 95 enrolled
patients16 to determine the level of statistical confidence we would have in our results based on a
final sample size of 150 patients. For a somewhat conservative estimate, we assumed that we
would have a final sensitivity of 80% and 85%.

Past-year severe IPV:
We determined that if the sensitivity were 80%, then the estimated 95% confidence interval (CI)
would be 61.9% - 91.9%.
If sensitivity was 85%, then the estimated 95% CI would be 69.2% - 95.8%.

Lifetime IPV:
If the sensitivity was 80%, then the 95% CI would be 68.9% - 88.0%.
If the sensitivity was 85% then the 95% CI would be 74.8% - 92.1%.
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The confidence intervals were estimated to be wider for aim 2, which was determined to limit the
power to measure differences among the racial/ethnic groups. However, we concluded that it
would still be valuable to examine the sensitivity and specificity for the different groups, along
with the confidence intervals, since this had not been studied previously.
Results:
We compared the validity of the PVS versus the CTS2 for measuring severe IPV in four
population groups. The first analysis examined all women in the study, regardless of race. The
second, third, and fourth analyses examined Native American, Hispanic, and White, nonHispanic populations individually.

Within each of these four categories, IPV was divided into severe physical IPV, and any severe
IPV. In the total sample, we assessed both lifetime and past-year IPV. For the Native American,
Hispanic, and White, non-Hispanic populations, we only assessed lifetime IPV because of
limited sample sizes to adequately assess past-year IPV.

All Races:
For the entire sample, the sensitivity of the PVS for detecting any lifetime severe IPV was 80.6%
(95% CI of 70.8-87.8%) and the specificity was 95.1% (95% CI of 88.5-98.2%). The sensitivity
of the PVS for detecting severe lifetime physical IPV, was 83.0% (95% CI: of 73.1% - 89.8%)
and the specificity was 93.4% (95% CI: of 86.4-97.1%).

For the entire sample, the sensitivity of the PVS for detecting any past-year severe IPV was
70.3% (95% CI: 52.8-83.6%) and the specificity was 97.4% (95% CI: 92.1 - 99.3%).
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The sensitivity of the PVS for detecting severe past-year physical IPV was 83.9% (95% CI: of
65.5-93.9%) and the specificity was 97.6% (95% CI: of 92.5-99.4%).

Native Americans:
Among Native American women, the sensitivity of the PVS for detecting any lifetime severe
IPV was 77.8% (95% CI: of 57.26- 90.62%) and specificity was 96% (95% CI: of 57.2690.62%). The sensitivity and specificity of the PVS for detecting women who experienced
lifetime severe physical IPV was 77.8% (95% CI: of 57.3-90.6%) and 96% (95% CI: of 77.799.8%), respectively.

White, Non- Hispanic:
The sensitivity and specificity of the PVS for detecting those who experienced any lifetime
severe IPV was 85.7% (95% CI: of 66.4- 95.3%) and 95.2% (95% CI: 82.6-99.2%), respectively.
The sensitivity of the PVS for detecting lifetime physical IPV was 88.0% (95% CI: of 67.696.8%) and a specificity of 91.1% (95% CI: of 77.9-97.1%).

Hispanics:
The sensitivity of the PVS for detecting women who experienced any lifetime severe IPV was
77.8% (95% CI: of 60.4- 89.3%); specificity was 93.5% (95% CI: of 77.2-98.9%). Sensitivity
(82.4% [95% CI: 64.8-92.6%]) and specificity (94.0% [95% CI: of 78.4-98.9%]) of the PVS
were similar for detecting severe lifetime physical IPV.
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Positive Predictive Value:
The positive predictive value (PPV) is important for clinicians as it reflects the probability that a
positive test actually reflects IPV experienced in the patient population. In our sample of female
trauma patients, the PPV was 90-93.8% for any severe IPV or physical severe IPV regardless of
time period assessed (lifetime or past year). Within racial/ethnic groups, PPV was similarly high
(92.3-95.5%) for lifetime severe IPV
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Discussion:
The data obtained from this study support our hypothesis that the PVS is a valid screening tool
for measuring severe IPV in female trauma patients. Similar to findings of prior studies, we
found that the PVS had a sensitivity of 80% and specificity of 95.1% in our total sample
population for detecting any lifetime severe physical IPV and a sensitivity of 83% and specificity
of 93.4% for detecting physical lifetime severe IPV. Feldhaus et al17 determined that the PVS had
a sensitivity of 71.4% and specificity of 84.4% when compared to the CTS for detecting past
year IPV. Koziol-McLain et al18 showed that the PVS had a sensitivity of 80% and a specificity
of 93% when compared to the CTS2 for predicting future severe IPV based on a survey
questioning past year IPV. Houry et al further demonstrated the validity of the PVS and its
ability to predict future violence by reporting women who screened positive for IPV were 11.3
times more likely to experience physical IPV and 7.3 times more likely to experience verbal
aggression compared to women who screened negative on the PVS.20

Our study not only examined the validity of the PVS in the general female trauma population,
but also in specific racial/ethnic groups. Although the sensitivity for detecting any lifetime
severe IPV in Native Americans and Hispanics was lower than he sensitivity of Non-Hispanic
whites, the 95% CI were wide indicating true sensitivity may not be the same for these groups..
These findings suggest that the PVS is good screening tool for detecting lifetime IPV in Native
American and Hispanic populations.

When examining the population as a whole, the sensitivity of the PVS for detecting women who
experienced any past-year severe IPV was substantially lower (70.3%) than the sensitivity of the
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PVS for detecting past-year severe physical IPV (83.9%). In order to account for this disparity,
we examined the wording of the questions in both the PVS and the CTS2. The PVS asks “Have
you ever been hit, kicked, punched, or otherwise hurt by someone?” The PVS does not
specifically ask about severe sexual violence or severe injury as does the CTS2. After further
examining the responses from our participants, the specific wording seemed to be the major
contributing factor to this difference in the data. Another possible explanation for the disparity
could be cultural differences between Native Americans and Hispanics versus Whites. In these
cultures, especially Native American cultures, it can be taboo to talk about IPV.

We also found that there is an advantage to using the PVS versus the CTS2. The PVS not only
asks about violence inflicted by an intimate partner, but also violence from non-partners. Since
our study did not look at violence from non-partners, these data were not included in our results.

Based on our results and the overwhelming rates of IPV in the population, we recommend that
the PVS be used as a screening tool for measuring intimate partner violence in female trauma
patients. The PVS is short and concise, which makes it useful in trauma situations. Because the
PVS does not ask about severe sexual violence or severe injury, it might be recommended to reword the initial question on the PVS include these types of violence. A possibility could be
“Have you ever been threatened, hit, kicked, punched, forced to have sex or other wise hurt by
someone?” An additional question could be included for positive responses asking about visits to
the doctor or hospitalization occurring from these actions. It may also be helpful to prompt the
patient to think about all relationships including intimate partners such as a boyfriend, fiancé,
men or boys they have dated as well as a current partner before administering the PVS. By
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doing this, we may be able to help the patient to remember a situation that occurred a long time
ago, or a situation that may have only occurred once.

The results from this study further support the evidence that routine screening needs to increase
in health care settings. The high rates of IPV in the Hispanic and Native American populations
indicate that more needs to be done in terms of education, prevention and treatment for this
major public health issue. More training needs to be implemented for physicians as well as
medical students. In a study examining medical student’s attitudes about experiences and
practices regarding IPV, although 91% reported receiving at least some training, only one fifth of
the population studied felt they had extensive training.26 Only about 30% of medical students
reported that they felt highly confident about talking to their patients about IPV.26 A report
issued by the Association of American Medical Colleges in 2004 stated that 20% of graduating
physicians felt that curriculum addressing the issue of IPV was inadequate.

Strengths and Limitations:
Our study has many strengths. Because of New Mexico’s highly diverse population, we were
able to sample a greater number of Hispanic and Native American women as compared to other
studies about IPV. The data that were collected has the potential to influence prevention,
screening and treatment of IPV. This study can also promote further research in IPV especially
in New Mexico and other areas with high populations of Native Americans and Hispanics. New
Mexico also has a high rate of IPV, making it an ideal place to conduct research on IPV in order
to help decrease the rates and provide services for victims.
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There are a few limitations to consider in this study. We were only able to collect 197 surveys
by the close of the study. Our final sample size was primarily limited by the number of women
who were admitted to the UNMH trauma service during the study period. Because our sample
size was limited, we were not able to assess the validity of the PVS for assessing past-year IPV
among Native Americans or Hispanics.

Survey administration could have also played in role in the lower sensitivities that were seen in
the Native American and Hispanic populations. Thackery et al demonstrated that White and
African American women surveyed were more comfortable with a female screener than a male
screener.11 It was also shown that both White and African American women are more
comfortable being screened by women of their own race. 11 The Hispanic and Native American
sample was too small in their study to adequately analyze preferences in these populations.
These preferences could have played a role in our study. Out of the 5 screeners who
administered the survey, one screener was male and only one woman was of Hispanic/Latino
descent.
Recall and reporting bias also need to be considered as the PVS and CTS2 are based on self
report.

Conclusion:
Although the PVS seems to be a good screening tool overall, improvements could be made in
order to increase sensitivity, particularly for assessment of past-year non-physical IPV. Further
studies need to be conducted in Hispanic and Native American populations to further investigate
prevalence rates, screening methods, and prevention and screening programs. In order to
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increase screening, implementation of prevention programs and to better understand how to help
victims of IPV, more extensive training needs to be provided to physicians starting at the medical
school level and beyond. By creating a better screening tool, we could not only help to identify
those women in the general population who have experienced IPV, but also those in minority
populations who have very high rates. Quick, easy to administer screening tools are necessary to
ensure that we provide adequate care for our patients in all fields of medicine.
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Table 1- The Revised Conflict Tactics Scales (14 questions, severe items) and the Partner
Violence Screen. Questions were modified to measure IPV in the past 12 months and lifetime.
Revised Conflict Tactics Scale- Severe Items
For past-year questions: Now I would like to ask you
about things that may have happened with your (main
partner) in the past 12 months, even if it only happened
recently or may have stopped altogether.
( Card E)
For ever questions: For people answering no to past year
for each item or for women without current partner: Now
I would like to ask you about all of the intimate or
romantic relationships you’ve had with men in your
lifetime, including when you were a teenager. This
includes past husbands, boyfriends or men or boys you
have dated as well as you current partner.

Partner Violence Screen

1. My partner used force (like holding me down or using a weapon)
to make me have sex
Past 12 months*
Never…………..0
1 time………….1
2 times………...2
3-5 times………3
6-10 times…….4
11-20 times…...5
>20 times……..6
Lifetime
Ever Yes……...1
Ever No………0
2. My partner threatened me with a knife or gun

1. Have you ever been hit, kicked, punched, or otherwise hurt
by someone?
No (skip to 2)……………………………....0
Yes but not in the last year…….1
Yes in the last year……………..2

3. My partner used a knife or gun on me

(An introduction is not provided before the PVS).

1a. Was it by a current or former intimate partner or spouse?
No………………………………0
Yes former partner……………..1
Yes current partner……………..2

2. Do you feel unsafe in your current relationship? (SKIP IF
NO CURRENT PARTNER)
Yes……………………………..1
No……………………………...0
3. Is there a partner from a previous relationship who is making
you feel unsafe or afraid now?
Yes…………………………….1
No……………………………..0

4. My partner kicked me, bit me, or hit me with a fist
5. My partner burned or scaled me on purpose
6. I went to a doctor because of a fight with my partner
7. I needed to see a doctor because of injuries caused by my partner
but didn’t go
8. My partner used threats to make me have sex
9. My partner gave me a bloody lip or black eye
10. My partner choked me
11.My partner slammed me against a wall
12. My partner beat me up
13. I passed out from being hit in the head by my partner
14. I had a broken bone because of a fight with my partner
* These response categories were included with every question in the CTS2 in order to assess IPV in the past 12
months and lifetime IPV.
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Table 2. Sensitivity, specificity, and positive predictive value of the Partner Violence Screen (PVS) versus CTS2 for measuring severe IPV, by time period
assessed
Population

IPV Type

All races

Any lifetime
severe –IPV
Physical
lifetime severe
IPV

80.6%

70.9-87.8%

95.1%

88.5-98.2%

93.8%

83.0%

73.1-89.8%

93.4%

86.4-97.1%

91.3%

86.8%

90.0%

91.2%

Any past-year
severe IPV

70.3%

52.8-83.6%

97.4%

92.1-99.3%
90.0%

96.0%

Physical pastyear severe
IPV

83.9%

65.5-93.9%

97.6%

Any lifetime
severe
Physical
lifetime
severe IPV

77.8%

57.3-90.6%

96.0%

77.7-99.8%

95.5%

80.0%

77.8%

57.3-90.6%

96.0%

77.7-99.8%

95.5%

80.0%

Any lifetime
severe

77.8%

60.4-89.3%

93.5%

77.2-98.9%

93.3%

78.4%

Physical
lifetime severe

82.4%

64.8-92.6%

94.0%

78.4-98.9%

93.3%

83.8%

White,
Any lifetime
non-Hispanic severe
Physical
lifetime severe

85.7%

66.4-95.3%

95.2%

82.6-99.2%

92.3%

91.0%

88%

67.7-96.8%

91.1%

77.9-97.1%

84.6%

93.2%

Native
American

Hispanic

Sensitivity

95% CI

Specificity

95% CI

Positive Predictive
Value

Negative Predictive
Value
Formatted Table

84.5%

92.5-99.4%
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